EP0667150A1 — Venlamafaxine and its analogues for inducing cognition enhancement
Assigned to Wyeth · Expires 1995-08-16 · 31y expired
What this patent protects
This invention provides use of a compound to manufacture a medicament of inducing cognition enhancement. The compound is a 2-(1-hydroxycycloalkyl or 1-hydroxycycloalkenyl)-2-phenylalkylamine derivative having the formula: in which A is a moiety of the formula wh…
USPTO Abstract
This invention provides use of a compound to manufacture a medicament of inducing cognition enhancement. The compound is a 2-(1-hydroxycycloalkyl or 1-hydroxycycloalkenyl)-2-phenylalkylamine derivative having the formula: in which A is a moiety of the formula wherein the dotted line represents optional unsaturation; R₁ is hydrogen or alkyl; R₂ is alkyl; R₄ is hydrogen, alkyl, formyl, or alkanoyl; R₅ and R₆ are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R₇ is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
- Pristiq (Desvenlafaxine Succinate) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.